Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct;8(6):a006234. doi: 10.1101/mcs.a006234

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Wiedemann et al.; Published by Cold Spring Harbor Laboratory Press

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted reuse and redistribution provided that the original author and source are credited.

PMC Copyright notice

Figure 1. — Radiologic findings over the course of the disease. (A) Chest computed tomography (CT) scan at initial diagnosis. (B) Head magnetic resonance imaging (MRI) 4 mo after crizotinib start with oligoprogression in the right parotid gland. (C) Chest and cranial CT scans with multifocal progression after radiotherapy. (D) Chest CT scan showing response to alectinib. (E) Chest CT scan showing oligoprogression in the left breast 8 mo later. (F) Chest CT and head MRI showing multifocal progression after partial mastectomy. (G,H) Chest CT and head MRI showing multifocal progression under certinib and brigatinib. (I) Chest CT and head MRI showing multifocal progression under carboplatin-pemetrexed. (J) Chest CT showing response to lorlatinib. (K) Chest CT and head MRI showing multifocal progression under lorlatinib. (L) Chest CT showing multifocal progression under carboplatin-paclitaxel-bevacizumab-atezolizumab; the patient died 3 wk later. (L) Treatment line, (RT) radiotherapy, (PR) partial response, (SD) stable disease, (LN) lymph nodes.